TriSalus (TLSI) CEO Szela disposes 20,302 shares for tax withholding

Rhea-AI Filing Summary

TriSalus Life Sciences CEO and President Mary T. Szela reported routine share dispositions tied to tax withholding, not discretionary selling. On March 17, she disposed of 15,944 shares of common stock at $3.85 per share. On March 11, she disposed of 4,358 shares at $4.13 per share. A footnote explains these shares were sold to satisfy tax obligations from vesting restricted stock units and that the activity does not represent a discretionary sale. After these transactions, she directly holds 752,987 common shares.

Insider Trade Summary

Net Seller: 20,302 shares ($79,383)

Net Sell 2 txns

Insider Szela Mary T

Role CEO and President

Sold 20,302 shs ($79K)

Type	Security	Shares	Price	Value
Sale	Common Stock	15,944	$3.85	$61K
Sale	Common Stock	4,358	$4.13	$18K

Holdings After Transaction: Common Stock — 752,987 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Szela Mary T

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER COLORADO 80031

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		S		4,358(1)	D	$4.13	768,931	D
Common Stock	03/17/2026		S		15,944(1)	D	$3.85	752,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.

Remarks:

	/s/ Mary Szela	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did TLSI CEO Mary T. Szela report in this Form 4?

Mary T. Szela reported two dispositions of TriSalus Life Sciences common stock totaling 20,302 shares. According to the filing, the shares were sold solely to cover tax withholding obligations arising from vesting restricted stock units, rather than as discretionary open-market sales.

How many TLSI shares did Mary T. Szela dispose of and at what prices?

She disposed of 15,944 shares at $3.85 per share on March 17 and 4,358 shares at $4.13 per share on March 11. The filing notes these sales were connected to tax withholding obligations on vested restricted stock units.

Why were Mary T. Szela’s TLSI shares sold according to the Form 4 footnote?

The footnote states the reported shares were sold to satisfy tax withholding obligations linked to vesting restricted stock units previously granted to her. It specifically clarifies that these transactions do not represent discretionary sales by the reporting person.

How many TriSalus Life Sciences shares does Mary T. Szela hold after these transactions?

Following the reported transactions, Mary T. Szela directly holds 752,987 shares of TriSalus Life Sciences common stock. This post-transaction holding figure is provided in the Form 4 and reflects her remaining direct ownership after the tax-related dispositions.

Were the TLSI share transactions by Mary T. Szela open-market sales?

The transactions are coded as “S”, a sale in the open market or private transaction, but the footnote explains their purpose was to cover tax withholding on vested restricted stock units, indicating they were mechanical rather than discretionary sales.

What role does Mary T. Szela hold at TriSalus Life Sciences (TLSI)?

Mary T. Szela is identified as both CEO and President of TriSalus Life Sciences and also a director. These titles come directly from the Form 4 reporting-person details included with the disclosed stock transactions.